Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
Primary Purpose
Depressive Disorder, Major, Borderline Personality Disorder
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Left Dorsolateral Prefrontal Cortex (L-DLPFC)
Dorsomedial Prefrontal Cortex (DMPFC)
Sham Stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Depressive Disorder, Major focused on measuring Depression, Neuromodulation, Transcranial Magnetic Stimulation, Borderline Personality Disorder
Eligibility Criteria
Inclusion Criteria:
- Male or Female, between the ages of 22 and 65 at the time of screening.
- Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
- Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD II), or unspecified depressive disorder AND Borderline Personality Disorder, with a current Mood Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
- HAMD-17 and MADRS score of ≥20 at screening (Visit 1).
- TMS naive.
- Access to ongoing psychiatric care before and after completion of the study.
- Access to clinical rTMS after study completion.
- In good general health, as evidenced by medical history.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.
Exclusion Criteria:
- Pregnancy
- The presence or diagnosis of prominent anxiety disorder, personality disorder, or dysthymia
- Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)
- Current mania or psychosis
- Bipolar Affective Disorder I and primary psychotic disorders.
- Autism Spectrum disorder or Intellectual Disability
- A diagnosis of obsessive-compulsive disorder (OCD)
- Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.
- Urine screening test positive for illicit substances.
- Any history of ECT (greater than 8 sessions) without meeting responder criteria
- Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).
- History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.
- Untreated or insufficiently treated endocrine disorder.
- Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)
- Contraindications to MRI (ferromagnetic metal in their body).
- Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
- Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO)
- Treatment with another investigational drug or other intervention within the study period.
- Any other condition deemed by the PI to interfere with the study or increase risk to the participant.
Sites / Locations
- Stanford HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Sham Comparator
Arm Label
Left Dorsolateral Prefrontal Cortex (L-DLPFC)
Dorsomedial Prefrontal Cortex (DMPFC)
Sham stimulation
Arm Description
The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
Outcomes
Primary Outcome Measures
Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active L-DLPFC vs. sham aiTBS.
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS-C has an overall score range from 0-60, with higher scores corresponding to higher levels of depression.
Secondary Outcome Measures
Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active DMPFC vs. sham aiTBS.
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS-C has an overall score range from 0-60, with higher scores corresponding to higher levels of depression.
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by retention rates
Retention rates will be determined as research follow-up rate ≥80%
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by recruitment rate
Recruitment rate will be determined by actual recruitment/recruitment milestones
Safety of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by rate of suicidal behaviors
Rate of suicidal behaviors will be determined by number of participants that committed a SB/total number of participants
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04870255
Brief Title
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
Official Title
Modulating Probabilities: Prediction, Assessment, and Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 20, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).
Detailed Description
This project aims to measure and modulate a mood depressive episode (MDE) in individuals with borderline personality disorder (BPD) trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE). This study will test the antidepressant effect of aiTBS stimulation over the left dorsolateral prefrontal cortex (L-DLPFC), and aiTBS stimulation over the dorsomedial prefrontal cortex (DMPFC) compared with sham.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder, Major, Borderline Personality Disorder
Keywords
Depression, Neuromodulation, Transcranial Magnetic Stimulation, Borderline Personality Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized to receive: active L-DLPFC stimulation, active DMPFC stimulation, or sham stimulation. Group size ratio will be 1:1:1.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Left Dorsolateral Prefrontal Cortex (L-DLPFC)
Arm Type
Active Comparator
Arm Description
The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
Arm Title
Dorsomedial Prefrontal Cortex (DMPFC)
Arm Type
Active Comparator
Arm Description
The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
Arm Title
Sham stimulation
Arm Type
Sham Comparator
Arm Description
Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
Intervention Type
Device
Intervention Name(s)
Left Dorsolateral Prefrontal Cortex (L-DLPFC)
Intervention Description
Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).
Stimulation will be delivered using the Magventure Magpro X100 TMS system.
Intervention Type
Device
Intervention Name(s)
Dorsomedial Prefrontal Cortex (DMPFC)
Intervention Description
Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).
Stimulation will be delivered using the Magventure Magpro X100 TMS system.
Intervention Type
Device
Intervention Name(s)
Sham Stimulation
Intervention Description
Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.
Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.
Primary Outcome Measure Information:
Title
Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active L-DLPFC vs. sham aiTBS.
Description
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS-C has an overall score range from 0-60, with higher scores corresponding to higher levels of depression.
Time Frame
At baseline (pre-intervention), during the intervention and immediately after the intervention.
Secondary Outcome Measure Information:
Title
Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active DMPFC vs. sham aiTBS.
Description
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS-C has an overall score range from 0-60, with higher scores corresponding to higher levels of depression.
Time Frame
At baseline (pre-intervention), during the intervention and immediately after the intervention.
Title
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by retention rates
Description
Retention rates will be determined as research follow-up rate ≥80%
Time Frame
At baseline (pre-intervention), during the intervention and immediately after the intervention.
Title
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by recruitment rate
Description
Recruitment rate will be determined by actual recruitment/recruitment milestones
Time Frame
At baseline (pre-intervention), during the intervention and immediately after the intervention.
Title
Safety of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by rate of suicidal behaviors
Description
Rate of suicidal behaviors will be determined by number of participants that committed a SB/total number of participants
Time Frame
At baseline (pre-intervention), during the intervention and immediately after the intervention.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or Female, between the ages of 22 and 65 at the time of screening.
Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
Diagnosed with Major Depressive Disorder (MDD) or Bipolar II, or unspecified depressive disorder AND Borderline Personality Disorder or trait, with a current Mood Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
MADRS score of ≥20 at screening (Visit 1).
TMS naive.
Access to ongoing psychiatric care before and after completion of the study.
Access to clinical rTMS after study completion.
In good general health, as evidenced by medical history.
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.
Exclusion Criteria:
Pregnancy
The presence or diagnosis of prominent anxiety disorder, personality disorder, or dysthymia
Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)
Current mania or psychosis
Bipolar I Disorder and primary psychotic disorders.
Autism Spectrum disorder or Intellectual Disability
A diagnosis of obsessive-compulsive disorder (OCD)
Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.
Urine screening test positive for illicit substances.
Any history of ECT (greater than 8 sessions) without meeting responder criteria
Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).
History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.
Untreated or insufficiently treated endocrine disorder.
Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)
Contraindications to MRI (ferromagnetic metal in their body).
Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO)
Treatment with another investigational drug or other intervention within the study period.
Any other condition deemed by the PI to interfere with the study or increase risk to the participant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bora Kim, MD, MAS
Phone
650-800-6929
Email
borakim2@stanford.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Nick Bassano, MSW
Phone
650-800-6929
Email
nbassano@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nolan Williams, MD
Organizational Affiliation
Stanford University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
David Spiegel, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford Hospital
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Marie Batail, MD, PhD
Phone
650-497-3933
Email
jmbatail@stanford.edu
First Name & Middle Initial & Last Name & Degree
Romina Nejad, MSc
Email
rnejad@stanford.edu
First Name & Middle Initial & Last Name & Degree
Nolan Williams, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
20439832
Citation
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.
Results Reference
background
PubMed Identifier
8547583
Citation
George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6. doi: 10.1097/00001756-199510020-00008.
Results Reference
background
PubMed Identifier
8684201
Citation
Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27;348(9022):233-7. doi: 10.1016/s0140-6736(96)01219-6.
Results Reference
background
PubMed Identifier
27604566
Citation
Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, DeWilde KE, Wong E, Anticevic A, Tang CY, Iosifescu DV, Charney DS, Murrough JW. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology. 2017 May;42(6):1210-1219. doi: 10.1038/npp.2016.186. Epub 2016 Sep 8.
Results Reference
background
PubMed Identifier
24629537
Citation
Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, Voss HU, Casey BJ, Etkin A, Dubin MJ. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014 Oct 1;76(7):517-26. doi: 10.1016/j.biopsych.2014.01.023. Epub 2014 Feb 5.
Results Reference
background
PubMed Identifier
26717528
Citation
Green KL, Brown GK, Jager-Hyman S, Cha J, Steer RA, Beck AT. The Predictive Validity of the Beck Depression Inventory Suicide Item. J Clin Psychiatry. 2015 Dec;76(12):1683-6. doi: 10.4088/JCP.14m09391.
Results Reference
background
PubMed Identifier
30761601
Citation
Ballard ED, Reed JL, Szczepanik J, Evans JW, Yarrington JS, Dickstein DP, Nock MK, Nugent AC, Zarate CA Jr. Functional Imaging of the Implicit Association of the Self With Life and Death. Suicide Life Threat Behav. 2019 Dec;49(6):1600-1608. doi: 10.1111/sltb.12543. Epub 2019 Feb 13.
Results Reference
background
PubMed Identifier
31825760
Citation
Tello N, Harika-Germaneau G, Serra W, Jaafari N, Chatard A. Forecasting a Fatal Decision: Direct Replication of the Predictive Validity of the Suicide-Implicit Association Test. Psychol Sci. 2020 Jan;31(1):65-74. doi: 10.1177/0956797619893062. Epub 2019 Dec 11.
Results Reference
background
PubMed Identifier
31481688
Citation
Light SN, Bieliauskas LA, Taylor SF. Measuring change in anhedonia using the "Happy Faces" task pre- to post-repetitive transcranial magnetic stimulation (rTMS) treatment to left dorsolateral prefrontal cortex in Major Depressive Disorder (MDD): relation to empathic happiness. Transl Psychiatry. 2019 Sep 3;9(1):217. doi: 10.1038/s41398-019-0549-8.
Results Reference
background
PubMed Identifier
29560909
Citation
Baeken C, Duprat R, Wu GR, De Raedt R, van Heeringen K. Subgenual Anterior Cingulate-Medial Orbitofrontal Functional Connectivity in Medication-Resistant Major Depression: A Neurobiological Marker for Accelerated Intermittent Theta Burst Stimulation Treatment? Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):556-565. doi: 10.1016/j.bpsc.2017.01.001. Epub 2017 Jan 20.
Results Reference
background
PubMed Identifier
24388670
Citation
Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, Bakker N, Blumberger DM, Daskalakis ZJ, Kennedy SH, Flint AJ, Giacobbe P. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014 Aug 1;76(3):176-85. doi: 10.1016/j.biopsych.2013.10.026. Epub 2013 Nov 28. Erratum In: Biol Psychiatry. 2014 Sep 1;76(5):430.
Results Reference
background
PubMed Identifier
27378888
Citation
Duprat R, De Raedt R, Wu GR, Baeken C. Intermittent Theta Burst Stimulation Increases Reward Responsiveness in Individuals with Higher Hedonic Capacity. Front Hum Neurosci. 2016 Jun 16;10:294. doi: 10.3389/fnhum.2016.00294. eCollection 2016.
Results Reference
background
PubMed Identifier
31787757
Citation
Schmaal L, van Harmelen AL, Chatzi V, Lippard ETC, Toenders YJ, Averill LA, Mazure CM, Blumberg HP. Imaging suicidal thoughts and behaviors: a comprehensive review of 2 decades of neuroimaging studies. Mol Psychiatry. 2020 Feb;25(2):408-427. doi: 10.1038/s41380-019-0587-x. Epub 2019 Dec 2.
Results Reference
background
PubMed Identifier
30819549
Citation
Gartner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, Heuser-Collier I, Boker H, Hattenschwiler J, Seifritz E, Grimm S, Scheidegger M. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol. 2019 Apr;29(4):501-508. doi: 10.1016/j.euroneuro.2019.02.008. Epub 2019 Feb 26.
Results Reference
background
Learn more about this trial
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
We'll reach out to this number within 24 hrs